Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

Opportunities to build upon enhanced competition for medicines in the marketplace

July 27, 2017

Hatch-Waxman is expected to continue to spur robust brand and generic competition in the years to come.

Read More

Finding cures for incurable diseases

July 25, 2017

74 percent of the medicines in the pipeline have the potential to be first-in-class therapies.

Read More

Medicare Monday: How Part B has evolved over the years

July 24, 2017

The ways reimbursement for physician-administered medicines under Part B has changed since it was first created

Read More

Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey

July 24, 2017

In a world of global investment flows, securing a larger portion of the $150 billion invested.

Read More

New PhRMA resources chock full of biopharma industry facts

July 20, 2017

Did you know that PhRMA member companies invested $65.5 billion in research and development (R&D) in 2016?

Read More

New video: Patient and researcher fight JRA together

July 19, 2017

Patient and researcher fight JRA together in new GOBOLDLY video.

Read More

New report portrays flourishing pipeline

July 18, 2017

74 percent of medicines in clinical development around the world are potentially first-in-class medicines.

Read More

New Report Shows 74 Percent of Medicines in Development have Potential to be First-in-Class Treatments

July 18, 2017

Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report.

Read More

Medicare Monday: What you need to know about the latest Medicare Trustees report

July 17, 2017

Takeaways from the 2017 Medicare Trustees report.

Read More

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

July 13, 2017

Study finds the 340B program accounted for nearly 8 percent of total U.S. branded outpatient drug sales in 2016.

Read More